Reality on the ground: - 6 quarters of cash remaining. - Cash outflow accelerated over the past two quarters: from -3 to -5 and now -6. The rest is cheap talk - Can you find quarterly receipts in this report? I wonder why: Q1: 3.1 => Q2: 2.9 => Q3: 2.6. Here we go with growth. What a spectacular FFFF. - Operational numbers minimal: clinical data and the ridiculous accumulative tests (slide #15) are presented instead. The arrow in slide #15 insults the reader: you expected the accumulative number of tests to decline? I can smell duplicity, weakness, and hiding from where I am sitting (which is quite distant). For me, it's time to wear the big boys' pants, sell, and cut losses.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)